Navigation Links
WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category
Date:4/21/2009

SARASOTA, Fla., April 21 /PRNewswire/ -- WellSpring Pharmaceutical Corporation announced earlier today that Emetrol (R), its liquid anti-nausea brand is now the leading product in its category. Based on trailing 52 weeks sales (ending 1/14/09) Emetrol(R) garnered 51.7 % of the brand category displacing all others including private label. The most recent IRI reports indicate that Emetrol (R) sales are up 24% over last year reflecting the fact that it is recommended by name by OB/GYN's, Pediatricians and Pharmacists. Over 90% of OB/GYN's interviewed indicate that they would most likely use Emetrol(R) as first line therapy in treating mild to moderate nausea.

For over 60 years, Emetrol(R) has provided consumers with reliable relief from nausea and vomiting. Emetrol (R) is popular with more and more consumers including women between the ages of 25 and 34 who seek Emetrol(R) due to their doctor or pharmacist's recommendation. Emetrol(R) is specifically recommended because it is safe, effective, and gives fast relief from nausea and vomiting due to upset stomach, flu, and food indiscretions. WellSpring has rolled out a national advertising campaign targeting this population segment. And the National Association of Pediatric Nurse Practitioners (NAPNAP) has selected Emetrol(R) for editorial content in their upcoming issue which reaches 3.5 million women ages 25-48.

WellSpring's President and CEO, Dr. Robert A. Vukovich commented on this announcement: "The Emetrol(R) brand is an important one for our company as we have seen remarkable growth in its sales over this past year. The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by Pediatricians for children under their care, has proven to be one of the most important attributes of the brand. Containing a unique combination of phosphorylated carbohydrates Emetrol (R) is considered by these physicians as safe and effective for treating mild to moderate nausea. We will continue to invest heavily in the brand with a new national advertising campaign."

WellSpring Pharmaceutical Corporation is a closely held pharmaceutical company marketing both prescription and non-prescription consumer drug brands. The firm has headquarters in Sarasota, Florida and operates a state-of-the-art GMP compliant manufacturing facility in Canada.

    Contacts:

    Wendy Shusko, COO 941-312-4727
    Wayne Miller, VP Sales 941-312-4727

    WellSpring Pharmaceutical Corporation
    5911 North Honore Ave., Ste 211
    Sarasota, Fl  34243

Emetrol Website: www.emetrol.com


'/>"/>
SOURCE WellSpring Pharmaceutical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
2. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
3. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
4. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
5. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
6. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
7. Strativa Pharmaceuticals Provides Product Pipeline Update
8. Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
10. Sun Pharmaceutical Extends Tender Offer for Taro
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: